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Abstract
Background: Following the decline of malaria transmission in many countries and regions, serological parameters
have become particularly useful for estimating malaria transmission in low-intensity areas. This study evaluated a
novel serological marker, Malaria Random Constructed Antigen-1 (M.RCAg-1), which contains 11 epitopes from
eight Plasmodium falciparum antigens, as a tool for assessing malaria transmission intensity along the border area of
China-Myanmar.
Method: Serum from Plasmodium falciparum and P. vivax patients was used to detect the properties of M.RCAg-1
and antibody responses. Cross-sectional surveys were conducted at the China-Myanmar border and in Hainan
province in 2012 and 2013 using cluster sampling. Filter blood spot papers were collected from all participants.
Antibodies against M.RCAg-1 were detected using indirect ELISA. The Mann–Whitney test and Spearman’s rank
correlation test were performed to analyze antibody data. P. falciparum malaria transmission intensity was estimated
using a catalytic conversion model based on the maximum likelihood of generating a community seroconversion
rate (SCR).
Results: M.RCAg-1 was well-recognized by the naturally acquired anti-malaria antibodies in P. falciparum patients
and had very limited cross-reactivity with P. vivax infection. The total amount of IgG antibodies was decreased with
the decrease in parasitemia after taking medication and lasted several weeks. In a population survey, the antibody
levels were higher in residents living close to the China-Myanmar border than those living in non-epidemic areas
(P < 0.0001), but no significant difference was observed between residents from Hainan and non-epidemic areas.
The calculated SCR was 0.0128 for Jieyangka, 0.004 for Susuzhai, 0.0047 for Qiushan, and 0.043 for Kayahe. The
estimated exposure rate obtained from the anti-M.RCAg-1 antibody level correlated with traditional measures of
transmission intensity derived from altitude.
Conclusion: Our study demonstrates that M.RCAg-1 is potentially useful as a serological indicator of exposure to P.
falciparum malaria, especially for malaria surveillance in low transmission areas.
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Background
Approximately 3.3 billion people are still at risk for
malaria globally, most of them infected by Plasmodium
falciparum (Pf ) [1], even though the malaria burden has
decreased after a long-term effort implemented in en-
demic areas. In recent years, many countries and regions
that were threatened by malaria previously have entered
a malaria-eliminating stage [2]. Unlike malaria control,
malaria elimination needs to interrupt local mosquito-
borne malaria transmission within a defined geograph-
ical area with no incidence of locally contracted cases
[3], which makes effective surveillance and transmission
intensity tracing necessary at this stage. Accurate assess-
ment of the Pf transmission intensity can help us under-
stand the disease burden and the risk of being infected,
provide guidance for control and prevention strategies
and confirm an area is Pf malaria-free with reliable
evidence. Until now, the industry standard for malaria
transmission intensity has been entomological inocu-
lation rate (EIR), which is time-consuming, expensive,
and imprecise in low-transmission districts [4]. Other
methods, such as climate-based models, parasite preva-
lence, and mean hemoglobin concentration, indirectly re-
flect Pf transmission intensity. However, these methods
are not sensitive enough in communities and are inaccur-
ate, especially in areas of low transmission.
To efficiently assess malaria transmission and endem-
icity, many researchers have suggested that serological
parameters offer more advantages than other ap-
proaches, such as EIR [5–8], because antibodies depend
on exposure to malaria infection and can persist for a
long time. Therefore, this tool could allow us to detect
changes in malaria transmission over time and monitor
the effectiveness of malaria control programs. However,
whether an appropriate serological marker can be se-
lected is the critical core of this method. Various malaria
antigens have been used as serological markers [9, 10],
including apical membrane antigen-1 (AMA-1), merozo-
ite surface protein-2 (MSP-2), and merozoite surface
protein-119 (MSP-119). Antibodies elicited by these well-
characterized Pf antigens have been tested at relatively
stable rates in some communities. However, each of the
individual antigens has its own limitations. For example,
MSP-2 with a high rate of polymorphism [11, 12] will
underestimate the seroprevalence with population differ-
ences [13]; saturation of antibody prevalence is easy to
achieve with AMA-1 with high immunogenicity [14],
even at moderate malaria endemicity, which makes them
effective in areas of extremely low endemicity or for
determining the extent of malaria epidemics [15]; and
MSP-119 has been used to estimate Pf malaria transmis-
sion in many African areas [16], but the antibodies to
this antigen can persist for years, with a half-life of
nearly 50 years, so this sluggish response to changes
make it inappropriate for assessing deviations in Pf
transmission in the short-term. Considering of great in-
dividual variations in antibody responses and multiple
malaria antigens expressed during the process of Pf
infection [17], antibody responses to single antigens are
circumscribed and inadequate as biomarkers for indicat-
ing malaria transmission intensity [18]. A multiplex
assay based on Luminex technology, which can detect
multiple antigens simultaneously, have been developed
and used for a long time [19–22]. However, the high in-
vestment costs and complex operations may prevent it
from being widely used.
More novel serological biomarkers are being found
that can accurately estimate recent Pf exposure for not
only communities [23], but also individuals. However,
the detection of antibodies to several antigens is also a
relatively big job, and the polymorphic reaction to these
natural antigens of Pf in different populations is still dif-
ficult to avoid. Our lab has successfully constructed a
multi-epitope chimeric protein, Malaria Random Con-
structed Antigen-1 (M.RCAg-1) [24], which contains 11
relatively conservative epitopes from eight Pf antigens.
This chimeric antigen was selected from a DNA library
containing thousands of diverse multi-epitope chimeric
antigen genes constructed using epitope shuffling and an
isocaudamer technique due to its high specific immuno-
genicity and anti-parasite efficacy [25].
The objective of this study was to estimate whether
M.RCAg-1 can be used as an indicator of Pf malaria
transmission dynamics. Using a simple indirect ELISA,
we detected anti-M.RCAg-1 antibodies in the serum of
Pf-infected patients from Pf malaria endemic areas or
non-endemic areas. The serological parameter obtained
in our study demonstrated that this chimeric antigen




Serum samples were collected from malaria patients in
Laza, Myanmar, between September and December 2008
to detect antibody responses against M.RCAg-1. The
patients were diagnosed by microscopic examination of
Giemsa-stained blood smears and treated promptly with
the appropriate antimalarial and supportive therapy.
Four plasma samples were collected from each patient:
prior to drug therapy (D0), the first day of treatment
(D1), the third day after treatment (D3), and the seventh
day after treatment (D7). A Giemsa-stained blood smear
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was prepared at the same time plasma samples were col-
lected. Plasma was used for the detection of antibody
against M.RCAg-1 and epitopes. Giemsa-stained blood
smears were used to determine parasitemia levels and
the Plasmodium species. A total of 67 Pf patients and 38
Plasmodium vivax (Pv) patients were enrolled in the
study. The population details have been described else-
where [26].
Study sites
This study comprised two cross-sectional surveys con-
ducted in the border area of China-Myanmar and
Hainan province of China. The border area in Yunnan
province with Myanmar [27, 28] was the most challen-
ging area in which to achieve the final goal of a malaria-
free China by 2020 as planned by the Chinese Center for
Disease Control and Prevention. The malaria transmis-
sion intensity in these areas, especially Pf malaria, has
decreased significantly in recent years because of the
implementation of malaria control strategies. Only 15 in-
digenous Pf malaria cases were reported in Yunnan
province in 2012–2013 [29]; thus, the sensitivity of
traditional methods, such as EIR and parasite preva-
lence, is limited in this area. However, the number of
indigenous Pf malaria cases was much greater in Laza,
Myanmar, than Yunnan province in China; 415 Pf
malaria cases were reported in 2012–2013 [30]. One
village (Jieyangka) in Laza was selected; considering that
malaria transmission is influenced by altitude, three
villages at various altitudes in Yunnan were selected:
Susuzhai (altitude 1 660 m), Qiushan (1 160 m), and
Kayahe (210 m). The climates of these villages, such as
temperature and rainfall, also vary (Fig. 1).
Hainan province used to be a malaria endemic area
with the highest disease burden, but no locally acquired
Pf malaria case has been reported since 2010 [31, 32]. In
this study, we chose Danzhou of Hainan as a control for
the historical Pf epidemic area.
Design and participants
Cluster sampling was used in this study, and residents in
all age groups were included from each village. Pregnant
women were excluded from this study. All participants
were requested to provide finger blood for immediate
Fig. 1 The information of research sites. a the specific locations of villages selected in this study. One village (Jieyangka) in Laza, Myanmar, three
villages (Susuzhai, Qiushan and Kayahe) in Yunnan province, China. b the altitudes of three villages in Yunnan. c the annual average temperature
and annual rainfall in the three villages selected in Yunnan
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microscopy (thick and thin blood smears) and dried
blood spots on filter paper (Whatman 3MM Chr) for
subsequent serological tests. Two professional microsco-
pists diagnosed all of the participants independently
after reading the blood films. All of the blood filter pa-
pers were put in sealed plastic bags and stored at −80 °C
after being dried at room temperature with abundant
self-indicating silica desiccants. Information on gender
and age was recorded.
Non-epidemic controls
A total of 108 healthy volunteer donors from the
General Hospital of Chinese People’s Liberation, Beijing,
China, who had never been exposed to malaria were
chosen as non-epidemic controls. Blood plasma and
dried blood spots were prepared from each control. The
plasma was used as a control for the plasma from mal-
aria patients and the blood spots as a control for the
dried blood spots collected from study sites.
Ethical approval
Ethical approval was received from the Institutional
Review Board (IRB) of the Institute of Basic Medical
Sciences, Chinese Academy of Medical Sciences. In-
formed consent was obtained from all participants, and
from guardians for children <15 years of age.
Antigens and epitopes
M.RCAg-1 proteins were produced in Escherichia coli
and prepared and purified by the Institute of Process
Engineering, Chinese Academy of Science. The purity of
the protein was verified through HP-SEC and RP-HPLC
analysis and the stabilities examined by SDS-PAGE at
regular intervals. All batches of proteins we obtained
had good stability with purity >95 %. All epitopes were
synthesized by China Peptides Co., Ltd, and the quality
confirmed through mass spectrometry and HPLC ana-
lysis. The purity of all of the epitopes (from Epitope-1
to Epitope-11) included in the M.RCAg-1 protein was
>95 %. All proteins and epitopes were split charged and
stored at −80 °C.
Elution of antibodies from dried blood spots
Antibodies were recovered from the blood spots following
a propositional method [33]. Plastic bags containing blood
spots were allowed to return to ambient temperature be-
fore opening and to check whether the silica desiccants
remained blue. One disc approximately 3 mm in diam-
eter was cut from each filter paper using a leather
punch and placed in 1 000 μl of 3 % sheep serum dis-
solved in PBS–0.05 % Tween 20 (PBS-T). The solution
was kept at 4 °C overnight with gentle mixing, and
then used immediately for antibody detection or stored
at −80 °C. The concentration of eluted serum proteins
was equivalent to a 1:1000 dilution of the serum.
Antibody assays
IgG antibodies to M.RCAg-1 protein and its epitopes
were measured by indirect ELISA. Briefly, M.RCAg-1
was dissolved in 0.1 M Na2CO3 (pH 9.2) at 1 μg/ml (or
5 μg/ml for epitopes), coated on high absorbance plates
(Corning), and kept at 4 °C overnight. After washing
five times with PBST, the plates were blocked with
3 % (vol/vol) sheep serum in PBS following incubation for
2 h at 37 °C. Plasma diluted 1∶200 with blocking buffer
or 100 μl of eluate from blood spots was added in dupli-
cate and incubated and washed as described above. Next,
the plates were incubated with peroxidase-conjugated goat
anti-human IgG antibodies (Sigma) at a dilution of 1∶20
000. H2O2 with tetramethylbenzidine (TMB; Sigma) was
chosen as the chromogenic substrate and the reaction ter-
minated with 1 M H2SO4 after 10 min. The optical density
(OD) was determined at both 450 and 630 nm using a mi-
croplate reader (Wellscan MK3, Labsystems Dragon,
USA). Each plate contained three negative control serum
samples from Beijing donors who had never been exposed
to malaria and two positive control serum samples from
malaria patients with high antimalarial antibody concen-
trations. All antibody values were expressed in arbitrary
units (AU) calculated by dividing the mean OD by the
mean OD+ 3 standard deviations (SDs) for the three
negative controls tested simultaneously. These relative
OD values were referred to as OD %.
Data processing and statistical analysis
Differences between the antibody concentrations of two
groups were analyzed using the Mann-Whitney test.
Spearman’s rank correlation test was used to test the re-
lationship between antibody levels and different factors,
including altitude, age, and parasitemia. The mean titer
of the non-epidemic controls + 2 SDs was set as the cut-
off and the antibody data dichotomized as seronegative
or seropositive. A simple reversible catalytic model was
fitted to the dichotomized data using maximum likeli-
hood methods [34]. The model generates a seroconver-
sion rate (SCR or λ) and a seroreversion rate (ρ). For
this study, only the SCR was allowed to vary when
models were fitted independently for each village; the
seroreversion rate was fixed because independent rever-
sion rates for each village did not improve the fit com-
pared to using a common rate of reversion [16]. In each
village, the 0–2 years age group was deleted because of
distortions caused by the presence of maternal anti-
bodies in highly endemic villages. Statistical analyses
were carried out using IBM SPSS Statistics 19 for
Windows and the above-mentioned models fitted using
the Solver add-in in Excel (Microsoft Office, 2010).
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Results
Study population
Details about the study population are given in Table 1.
Fewer men were sampled than women in Jieyangka, but
in Yunnan and Hainan the gender distribution was
balanced. Samples from each village contained all age
groups, except no children <5 years of age were sampled
in Danzhou. The specific age distribution varied depend-
ing on the cluster, and the proportion of children under
5 years old was 27.3 % in Jieyangka, which is obviously
higher than the proportions in other villages. A total of
15 Pv infections were detected in Jieyangka and 5 in
Qiushan, Yunnan. No clinical symptom, such as fever,
occurred. As no Pf infection was detected in the partici-
pants, it confirmed that the Pf malaria transmission in-
tensity was low in all of these areas and the parasite
prevalence not suitable for estimating the Pf malaria
exposure level in these areas.
Antibody response in serum from malaria patients
To investigate M.RCAg-1-specific antibody responses,
we collected serum from malaria patients in Laza in
2008 before they took medicine (Fig. 2). The IgG anti-
body levels were predominantly higher in Pf patients
than in Pv patients (P < 0.0001) and negative controls
(P < 0.0001), and there was very limited cross-reactivity of
M.RCAg-1 with Pv infection (Fig. 2a). The average anti-
body levels in Pf patients grouped by onset time are
shown in Fig. 2b. These results suggest that anti-M.RCAg-
1 antibody can be stimulated once malaria occurs and
maintained at a certain concentration during the infection,
though with some fluctuation. The levels of antibody to
epitopes of M.RCAg-1 were also tested (Fig. 2c). All 11
epitopes could be identified to varying degrees by the nat-
urally acquired antibodies in serum from Pf patients. A
negative correlation was found between antibody levels
and the parasitemia (r = -0.334, P < 0.05) in Pf patient
serum (Fig. 2d), indicating that the anti- M.RCAg-1 anti-
bodies offer immune protection against malaria.
Antibody variation after treatment
To understand the longevity of anti-M.RCAg-1 antibody
responses, we tested the antibody levels in serum sam-
ples taken from Pf patients at D0, D1, D3, and D7
(Fig. 3). The parasitemia decreased after taking medica-
tion (Fig. 3a), with an accompanying decrease in IgG
antibodies, but the antibody levels at D7, when no
parasites were detected, were still higher than in healthy
controls from non-epidemic areas (P < 0.0001) (Fig. 3b).
The longevity of anti-M.RCAg-1 antibodies was several
weeks, as estimated by data from acutely infected indi-
viduals following drug treatment in this study. Further-
more, the trend in antibody variation in each patient
presented good consistency (Fig. 3c), suggesting few
polymorphisms in M.RCAg-1.
Antibody detection in blood spots
To determine whether M.RCAg-1 can be used to esti-
mate exposure to Pf malaria, especially in low transmis-
sion areas, we tested the antibody levels in eluates from
blood spots collected from residents living in Hainan
province and along the China-Myanmar border. We
found no significant differences in the antibody levels of
residents from Hainan and participants from Beijing
(P = 0.176). However, on the China-Myanmar border, the
antibody levels of residents from the four villages were sig-
nificantly higher than the levels in participants from
Beijing (P < 0.0001). In the three villages in Yunnan prov-
ince, antibody levels decreased with increasing elevation
(r = −0.258, P < 0.0001 in 5-14-year-olds; r = −0.492,
P < 0.0001 in 15-30-year-olds; r = −0.356, P = 0.001 in
31-45-year-olds; and r = −0.473, P < 0.0001 in >45-
year-olds; Fig. 4a). The antibody concentrations increased
with increasing age (r = 0.421, P < 0.0001 in Jieyangka;
r = 0.435, P < 0.0001 in Susuzhai; r = 0.451, P < 0.0001
Table 1 The characteristics of study populations
Myanmar China
Laza Yunnan Hainan
Jieyangka n = 589 (%) Susuzhai n = 90 (%) Qiushan n = 500 (%) Kayahe n = 62 (%) Danzhoun n = 150 (%)
Gender Male 158(26.8) 44(48.4) 259(51.8) 24(38.7) 67(44.7)
Female 431(73.2) 46(51.6) 241(48.2) 38(61.3) 83(55.3)
Age <5 161(27.3) 8(8.9) 8(1.6) 8(12.9) 0(0)
5–14 82(13.9) 12(13.3) 284(56.8) 12(19.4) 78(52)
14–25 35(5.9) 27(30) 28(5.6) 3(4.8) 15(10)
25–45 166(28.2) 20(22.2) 90(18) 18(29) 21(14)
>45 145(24.6) 22(24.4) 91(18.2) 21(33.9) 36(24)
Infection P. f 0 0 0 0 0
P. v 15 5 0 0 0
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in Qiushan; and r = 0.374, P = 0.003 in Kayahe;
Fig. 4b). No difference in antibody levels was found
between males and females for any of the villages
(P > 0.05).
Evaluating malaria transmission intensity
To obtain the parameter λ for each village, we calculated
the seroprevalence data for each settlement stratified by
age (Fig. 5), and then calculated the SCR using
maximum-likelihood fits from a reversible catalytic equi-
librium model (Fig. 6). Compared to the villages of Yun-
nan, the proportion of seroprevalence was higher in
children <14 years old from Jieyangka, suggesting that
the on-going Pf infection was more serious in this area.
The parameter ρ was set to 0 in this study [5]. Parameter
λ was 0.0128 for Jieyangka, 0.004 for Susuzhai, 0.0047
for Qiushan, and 0.043 for Kayahe. The age seropreva-
lence curve did not fit as well for Jieyangka as for the
villages of Yunnan, showing that the observed seropreva-
lence in children <14 years of age was above the pre-
dicted curve. Theoretically, models should be fitted by
two steps to calculate two forces of an infection profile
when visual examination of the SCR suggests it is not
uniform over the whole population, but finite-sized
samples in this study limited further calculation. There-
fore, the Pf malaria transmission in Jieyangka was under-
estimated here, especially in children under 14 years of
age. Importantly, we identified a semi-logarithmic rela-
tionship between the village-specific rate of seroconver-
sion (λ) and altitude, and the log (λ) linearly correlated
with log (EIR), which was estimated from altitude [35]
(Fig. 7).
Discussion
Even though serological biomarker detection is theoret-
ically the best tool for malaria surveillance, the proper-
ties of selected antigens are an important point of the
technique. Only sensitive and specific antibodies can ful-
fill the requirements for estimating the malaria exposure
level in a population precisely, monitor the changes over
time and the impact of intervention on transmission,
and confirm the elimination of malaria. The chimeric
antigen M.RCAg-1 was identified using malaria parasite-
immunized animal serum from a library containing
thousands of chimeric antigen genes [36]. This antigen
contains epitopes from eight Pf antigens that have been
shown to play essential roles in malaria immune re-
sponses [15, 18, 37–39]. High antigenicity and
Fig. 2 Antibody response to M.RCAg-1 and its epitopes in serums of malaria patients. a The IgG antibody levels against M.RCAg-1in Pv, Pf malaria
patients and normal controls. b The X axis was days between the date of malaria onset and the date taking treatment, the Y axis showed the
antibody levels. c Antibodies to all epitopes of M.RCAg-1. d The association between parasitemia and antibody levels
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immunogenicity has been demonstrated for M.RCAg-1
[24], and the antigenicity of individual epitopes included
in the chimeric antigen has also been shown [40, 41].
Our data demonstrate that M.RCAg-1 can be recog-
nized by serum from Pf-infected patients from Myanmar
but not the serum of healthy individuals from several lo-
cations in China, which is in line with previous data
from Brazil and Cameroon [24]. Our data also show that
all epitopes included in M.RCAg-1 can be recognized by
antibodies in the serum of Pf-infected patients, even if at
different levels, suggesting that M.RCAg-1 is a well-
recognized chimeric antigen to the naturally acquired
anti-malaria antibodies and has the advantage of few
polymorphisms. In addition, we found that anti-
M.RCAg-1 antibodies rapidly appeared in the sera of pa-
tients when the infection started, confirming the sensi-
tivity of M.RCAg-1 to Pf infection.
The specificity of sero-surveillance tests could be in-
fluenced by the potential cross-reactivity of antibodies to
antigens from different malaria species [42–44]. There-
fore, proper antigens must be either species-specific or
have substantial sequence diversity between species. As
Fig. 4 Anti-M.RCAg-1 antibody levels in different age groups and different study sites. a Grouped by age, to compare antibody levels of
individuals from different study sites. b Grouped by study site, to compare antibody levels of individuals with different ages
Fig. 3 Antibody variation with reduction of parasitemia after treatment. a The parasitemia in different days after treatment. bThe antibody levels
of P. falciparum malaria patients in different days. c The antibody variation trends in each patient after treatment
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our data show that anti-M.RCAg-1 antibody levels were
significantly higher in Pf-infected patients than Pv-in-
fected patients, we conclude that it is a Pf-specific sero-
biomarker when used in malaria sero-surveillance.
One of the potential disadvantages of the serological
approach is that, if antibody responses are very long-
lived (such as MSP-119), a serological assay may not dis-
tinguish significant recent deviations from the historic
pattern of transmission [16]. Some studies have shown
that, if not specifically focused on individuals with acute
infection, investigators usually report longer half-lives
than predicted from individuals with acute infection [45,
46]. In our study, we speculated that the longevity of the
anti-M.RCAg-1 antibodies fell into the range of weeks to
months, even with the addition of underestimated values
caused by the research objects. These data show that
M.RCAg-1 is suitable for estimating recent malaria
transmission intensity.
In endemic areas, a decrease in malaria transmission
will always wane the population immunity, which makes
the local residents vulnerable to outbreaks of this dis-
ease. Therefore, immune monitoring is necessary for
identifying the susceptible population and helping pro-
vide additional protective interventions, as demonstrated
by Richards, who showed that sero-surveillance has the
potential to indicate population immunity except expos-
ure [47]. In this study, we observed that parasitemia de-
creases with the accumulation of anti-M.RCAg-1
antibodies before treatment, as has been reported in sev-
eral prospective longitudinal studies in different parts of
Africa and Asia [48, 49]. Anti-M.RCAg-1 antibodies
have been suggested to have the potential to indicate
anti-malaria immunity.
In our study, all of the areas selected for evaluating
whether M.RCAg-1 can be used as a serological marker
were areas where Pf malaria transmission have been re-
ported to be dramatically decreased [50] and cannot be
estimated using traditional methods, such as EIR and
parasite prevalence. As our data showed that the anti-
M.RCAg-1 antibody levels were significantly higher in
Fig. 6 Age sero-prevalence plots for antibody responses to M.RCAg-1. The Maximum-likelihood fits of seroconversion (λ) from reversible catalytic
equilibrium model for each village are acquired. Observed and estimated age-specific prevalence of antibodies represent with real points and
dash line respectively
Fig. 5 Seroprevalence in different age groups and different
study sites
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participants from Yunnan and Laza than those from
Beijing, the serum samples from epidemic areas are sensi-
tive to this antigen, suggesting that M.RCAg-1 could be a
proper sero-biomarker for estimating low malaria trans-
mission intensity. In addition, because anti-M.RCAg-1
antibodies were not significantly different between resi-
dents from Hainan and Beijing, and considering that no
local-acquired case of Pf infection has been reported in
Hainan province since 2010, we conclude that M.RCAg-1
can be used to confirm the elimination of Pf malaria.
Moreover, the anti-M.RCAg-1 antibody levels increased
with the increasing age, which can be explained by the cu-
mulative exposure to malaria parasites over time [51, 52].
Altitude has long been assumed to represent a proxy
for malaria transmission [53] because there is a close re-
lationship between temperature and rainfall, which plays
important roles in the breeding of the malaria parasite
carrier, mosquitos. In addition, Bodker’s group declared
a highly significant decrease in the EIR with increasing
altitude (log(EIR) = 2.523–0.0025 * altitude) [35]. The
three villages we sampled close to the border of Yunnan
province are under the same prevention and control sys-
tem; therefore, the difference in malaria transmission in-
tensity among them must be caused mainly by the
altitude. Our study demonstrates that the estimated ex-
posure rate (SCR) determined by M.RCAg-1 correlates
with the traditional measure of transmission intensity
(predicted EIR), providing great evidence for the use of
M.RCAg-1 to estimate malaria transmission intensity.
From our studies, seropositivity is mainly due to adults
in Yunnan province in China, whereas the seropreva-
lence is high in children under 14 years of age in Laza,
Myanmar, meaning that the recent or on-going Pf
malaria exposure in Laza is much more serious than in
Yunnan. Our data are in line with a report on the mal-
aria situation in the same areas [30] that mentions that
varying socioeconomic status, medical conditions, and
control measures for malaria make the differences
between the two countries [30, 54].
Several reports have shown that using multiple anti-
gens or epitopes in sero-surveillance assays has advan-
tages over the use of one antigen [18, 47, 55]. Unlike
other multi-antigen detectors using either antigen-
coated beads or a mixture of several antigen proteins,
M.RCAg-1 can be prepared from the supernatant of an
E. coli expression system using a routine process. In
addition, to test the serum antibodies with an indirect
ELISA assay, all of these specialties make the task not
only simple, but also inexpensive.
Many challenges still exist for malaria elimination as
the focus shifts from the detection of symptomatic
patients to the detection and clearance of all infections.
Effective tests capable of estimating and monitoring
transmission intensity with high sensitivity and accuracy
in the field will play an important role. This study indi-
cates that multi-epitope chimeric antigens may have a
great advantage as serological markers to estimate Pf
malaria transmission. However, more investigations in
different populations are needed to confirm its useful-
ness and ensure the generalizability of results.
Conclusions
Our study demonstrates that the chimeric multi-epitope
antigen M.RCAg-1 has the potential as a sero-biomarker
to estimate the Pf malaria transmission intensity, espe-
cially at a fairly low level, to monitor its recent trends,
and to confirm the elimination of Pf malaria infection in
malaria surveillance systems.
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Fig. 7 Association between altitude or EIR and rate of seroconversion from M.RCAg-1 seronegative to seropositive. a Plot of estimated
seroconversion rates(λ) (calculated as for Fig. 6) against altitude. The line and R2 value are for the least-squares fitted functionλ = 0.0534e-0.002h,
where h is the altitude in m. b Plot of log(λ) against log (predicted EIR). The least-squares fitted line has the equation Log10(λ) = 0.01*Log10(EIR)-
2.3653. EIR was calculated from the equation log(EIR) = 2.523–0.0025 * altitude [35]
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